Sign inJoin waitlistJoin the waitlist

CK

Carl Koschmann

Physician · University of Michigan Health-Ann Arbor

Credentials: · · ·

History

University of Michigan Health-Ann Arbor
2019–Present

Seattle Children's Hospital
2010–2013
Internal Medicine
University of Washington School of Medicine
2007–2010
Univ of Wisconsin Sch of Med and Public Health
2003–2007

Research

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
Science Translational Medicine · 2016 · First of 24 authors · 230 citations
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
Science Translational Medicine · 2019 · 211 citations
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
Nature Genetics · 2022 · 173 citations

Sriram Venneti
40 papers
Rajen Mody
30 papers
Sabine Mueller
26 papers
AF
Andrea Franson
24 papers
HG
Hugh Garton
16 papers
PR
Patricia Robertson
16 papers
DW
Daniel Wahl
14 papers · 1 as a resident
Drew Pratt
12 papers
Nicholas Vitanza
12 papers
Mariella Filbin
11 papers
Cassie Kline
10 papers
Karin Muraszko
10 papers

Grants

Analytical and Clinical Validation of an H3K27M ctDNA Assay for Diffuse Midline Glioma (DMG) Surveillance
National Cancer Institute · UH2
Contact PI · $421.2K · University of Michigan at Ann Arbor
2025–2027
The Role of ATRX Mutation in the Epigenetic Dysregulation of Cell Cycle in Pediatric High-Grade Glioma
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $1.9M · University of Michigan at Ann Arbor
2021–2027
Targeting EGFR/FOXG1-Mediated Resistance to ONC201 in H3K27M-Mutant Diffuse Midline Glioma
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $2.2M · University of Michigan at Ann Arbor
2022–2027
Targeting ATRX-Deficient Pediatric GBM
National Institute of Neurological Disorders and Stroke · K08
Contact PI · $811.3K · University of Michigan at Ann Arbor
2016–2021

Clinical trials

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
Principal investigator · Withdrawn · Early phase 1
University of Michigan Rogel Cancer Center
2019–2021
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
Principal investigator · Withdrawn · Phase 2
University of Michigan Rogel Cancer Center
2019–2025
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
Principal investigator · Terminated · Phase 2
University of Michigan Rogel Cancer Center
2017–2019
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
Principal investigator · Terminated
University of Michigan Rogel Cancer Center
2013–2015